Join
Live feed
·
PRReleasevia Quantisnow
C4 Therapeutics Inc. logo

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population

ByQuantisnow·Wall Street's wire, on your screen.
CCCC· C4 Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CCCC (C4 Therapeutics Inc.) and more on Quantisnow.